Skip to main content
. Author manuscript; available in PMC: 2019 Mar 1.
Published in final edited form as: Hepatology. 2018 Jan 26;67(3):955–971. doi: 10.1002/hep.29371

Figure 8. β-catenin suppression by DsiRNA conjugated to N-acetylgalactosamine results in decreased liver injury due to reduced BA after BDL.

Figure 8

(A) WB shows decrease in β-catenin and GS protein levels after administration of GalXC-CTNNB1 after BDL. (B) Decreased serum ALP in β-catenin GalXC-CTNNB1-treated animals after BDL when compared to controls. (C) Liver TBA are decreased in β-catenin GalXC-CTNNB1treated livers. (D) H&E shows that bile infarcts are smaller in mice given BDL and treated with GalXC-CTNNB1 compared to controls. (E) Expression of direct FXR target SHP is significantly increased in GalXC-CTNNB1 treated livers after BDL, while indirect target Cyp7a1 is suppressed. (F) Analysis of BA species shows decreased TβMCA in livers of β-catenin GalXC-CTNNB1-treated mice after BDL (left), which results in a higher percentage of TCA in these livers when expressed qualitatively as a percentage of total BA (right). *p<0.05; **p<0.01; ****p<0.0001.